Latest Lenalidomide Stories
BURLINGTON, Mass., Dec.
NEW YORK, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
In two Phase 2 studies, perifosine achieves objective responses and high rates of stable disease as a single-agent in the treatment of Chronic Lymphocytic Leukemia (CLL), and in combination with sorafenib in the treatment of relapsed/refractory Hodgkin's Lymphoma (HL) QUEBEC CITY, Dec.
PALO ALTO, Calif., Dec. 6, 2010 /PRNewswire/ -- Telik, Inc.
The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 â€“ 6.
BURLINGTON, Mass., Sept.
EMERYVILLE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd.
EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
PALO ALTO, Calif., June 8 /PRNewswire-FirstCall/ -- Telik, Inc.
EMERYVILLE, Calif., June 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.